Clinical Trial Update: Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial evaluating pharmacogenomics-based proton pump inhibitor therapy in children for gastroesophageal reflux disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Proton Pump Inhibitors (pharmacogenomics-guided therapy)

Snippet

Sponsor: Osaka University | Conditions: Gastroesophageal Reflux | Phase 4 | Status: WITHDRAWN